School of Medicine
Showing 851-860 of 1,038 Results
-
William Shomali
Clinical Assistant Professor, Medicine - Hematology
BioDr. Shomali is a clinical assistant professor of Hematology at Stanford University School of Medicine. He is board certified in hematology & medical oncology.
Dr. Shomali specializes in the treatment of blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes. He aims to provide compassionate, personalized, and evidence-based care to each patient.
Dr. Shomali received his medical degree from the University of Jordan, followed by a postdoctoral fellowship at MD Anderson Cancer Center where he studied infections in cancer patients and the role of biomarkers in defining tumor fever. He completed his residency training in Internal Medicine at the Cleveland Clinic Foundation where he served as a Chief Medical Resident. He then joined Stanford University for his combined Hematology & Oncology fellowship training.
Dr. Shomali’s research interests include the study of novel agents in myeloproliferative neoplasms and myelodysplastic syndromes. He developed investigator-initiated clinical trials for patients with eosinophilic neoplasms and advanced myelofibrosis. In addition, he co-authored several papers and book chapters discussing the care of patients with cancer. His work has been presented in national meetings and published in peer reviewed journals including Blood, American Journal of Hematology, British Journal of Hematology, Leukemia & Lymphoma, and Cancer.
Among his honors, Dr. Shomali received the Cleveland Clinic Excellence in Teaching Award and was named to the Alpha Omega Alpha Medical Honor Society. He has received a Young Investigator Award from the Conquer Cancer Foundation, an NIH Institutional National Research Service Award, and a Stanford Cancer Institute Fellowship Award.
Dr. Shomali is a member of the American Society of Hematology and the American Society of Clinical Oncology. -
Aimee D. Shu
Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism
BioI am an endocrinologist with particular interests in reproductive and bone health.
I enjoy treating patients with menstrual disorders, menopause, fractures, osteoporosis, parathyroid imbalance, and calcium imbalance.
As a certified menopause practitioner (North American Menopause Society), I help women fine-tune their health at the mid-life transition. Some women transition through menopause with ease, while others experience challenging symptoms like hot flashes, slowed metabolism, and mood changes. This transition period provides a good opportunity to create a "game plan" for preserving future health. It also marks the beginning of natural bone loss, leaving one more susceptible to fragility fractures.
I provide individualized treatment plans for bone health to men and women of all ages, including for those with specific challenges such as chronic steroid use. As a certified clinical densitometrist (International Society for Clinical Densitometry), I personally review all my patients' bone density scan images. Thus, please bring any non-Stanford bone density scan images to your appointment with me.
Appointments with me are available on Stanford's main campus (300 Pastuer Drive) and at the Stanford Medicine Outpatient Center (450 Broadway, Redwood City). -
Takudzwa Shumba
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Takudzwa Shumba is a family medicine clinician-educator with particular interests in global health equity, preventative medicine, women's health, pediatrics and integrative medicine. She was born and raised in Zimbabwe. Prior to beginning medical school at Stanford, she completed a Master's in Public Health at Yale, with a focus in global health. She has been involved in public health projects in Zimbabwe, Hong Kong and mainland China and Kenya. She completed her residency at Stanford Health Care - O'Connor Hospital Family Medicine in San Jose, prior to joining faculty at Stanford Family Medicine. LGBTQQI friendly. After several years as a continuity primary care provider at Stanford Family Medicine, she transitioned to providing quality same day access for acute patient needs.
She is currently Co-director of the Leadership Education in Advancing Diversity (LEAD) program, Associate Director of the Clinical Summer Internship (CSI), Course Director of the undergraduate seminar “Decolonizing Global Health,” and Co-Director of the "Social and Environmental Determinants of Health" elective. She is a California Health Care Foundation (CHCF) Fellow (2020-2022) and Presidential Leadership Scholar (2022). She previously served as the Primary Care and Population Health (PCPH) Division Global Health faculty lead and PCPH DEI faculty lead. -
Anjali Sibley MD, MPH
Clinical Associate Professor, Medicine - Oncology
BioDr. Sibley is a Clinical Associate Professor of Medicine (Oncology) at Stanford School of Medicine. She is the Director of the Stanford Medicine Cancer Center in Emeryville and is a board-certified, fellowship-trained hematologist and medical oncologist.
Her clinical interests include treating solid tumor cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in hematologic/oncologic care among underserved populations, and successful cancer survivorship programs.
In addition to responsibilities related to patient care and overseeing the Cancer Center in Emeryville, Dr. Sibley has developed and is leading an innovative cancer survivorship clinic, including an exercise initiative. She also is passionate about advancing clinical trial enrollment for medically underserved populations and she serves on the Cancer Network’s East Bay Health Equity Committee leading lung cancer screening efforts in the East Bay. She is also working on a Stanford Cancer Institute-funded study examining psychosocial factors and cardiac health in Black cancer patients in the East Bay.
She believes that providing patient care is a true privilege. Dr. Sibley utilizes a patient-centered practice approach that addresses multiple aspects of a patient’s well-being. Her research interests have included chemoprevention of breast cancer and the development of magnetic resonance imaging technology in breast cancer detection and mapping. She has also led community-based efforts to implement low-dose computed tomography (LDCT) as a screening tool for cancer.
Dr. Sibley’s publications include articles on breast cancer prevention, breast magnetic resonance imaging, and other topics. Her work has appeared in American Journal of Hematology, JAMA, the Breast Journal, Internal Medicine News, and elsewhere. Dr. Sibley was invited to deliver a peer-reviewed presentation on community-based cancer screening and preventive education to the Global Health Council. Dr. Sibley is on the board of directors of the Cancer Support Community SF Bay Area. She has also served as a clinic physician for the Native American Health Center of Oakland, on the Committee on Health Equity of the American Public Health Association, and as chair and vice chair of the Cancer Forum Caucus of the American Public Health Association. She is a member of the American Society of Clinical Oncology, American Society of Preventive Oncology, and American Society of Hematology. She has provided volunteer services to the Global Health Council and to the Cancer Patients Aid Association, for whom she conducted a patient screening and education program in Mumbai, India. -
Surbhi Sidana, MD
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Sidana is a hematologist/oncologist who is fellowship trained in advanced hematology with an emphasis on myeloma, amyloidosis, and dysproteinemia disorders. She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine. She leads the Myeloma Cellular Immunotherapy program at Stanford.
Her areas of expertise include transplantation and novel cellular immunotherapies such as CAR-T-cell therapy for patients with multiple myeloma. For each patient, Dr. Sidana develops a personalized care plan designed to optimize outcomes and quality of life.
Dr. Sidana conducts extensive research. Currently, she is conducting clinical trials of CAR-T therapy and bispecific T-cell engagers for treatment of patients with myeloma. She is studying patients’ access to CAR-T cell therapy, the financial burden of the treatment, and its impact on patients’ quality of life and cognitive function.
Dr Sidana has received a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program to study adverse events of CAR-T therapy on patients and monitoring of patients undergoing CAR-T therapy using wearable devices.
In the past, Dr. Sidana received Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research on the impact of clinical trial participation on patients with multiple myeloma and lymphoma. She has also received grants from the Amyloidosis Foundation and International Waldenstrom’s Macrogloulinemia Foundation to understand AL amyloidosis, a rare disease caused by buildup of an abnormal protein.
Dr. Sidana has given presentations at regional and national conferences and her work has been published in high-impact journals.
Dr. Sidana has been recognized for her work with many honors, including an Outstanding Hematology/Oncology Fellow award and Outstanding Research Fellow award from the Mayo Clinic.
She is a member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and American Society of Transplantation & Cellular Therapy. Dr. Sidana is often an invited speaker at patient support groups as well as symposia and workshops for her peers. -
Branimir I. Sikic, M. D.
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers
-
Julia Fridman Simard
Associate Professor of Epidemiology and Population Health, of Medicine (Immunology & Rheumatology) and, by courtesy, of Obstetrics and Gynecology (Maternal Fetal Medicine)
BioJulia Fridman Simard, ScD, is an Associate Professor of Epidemiology & Population Health, and, by courtesy, of Medicine in Immunology and Rheumatology and Obstetrics and Gynecology in Maternal Fetal Medicine at Stanford University School of Medicine.
Dr. Simard earned her Masters and Doctorate of Science in Epidemiology degrees at the Harvard School of Public Health. During that time she trained with investigators at the Section of Clinical Sciences, Division of Rheumatology, Immunology, and Allergy at Brigham and Women’s Hospital and the Cardiovascular Epidemiology Research Unit at Beth Israel Deaconess Medical Center. In 2008, Dr. Simard relocated to Sweden to begin a Postdoctoral Fellowship in Clinical Epidemiology at the Karolinska Institutet in Stockholm. She became an Assistant Professor in their Clinical Epidemiology Unit in 2011, and was later honored with a Karolinska Institutet Teaching Award. Leveraging the population-based registers of Sweden, Dr. Simard initiated a national register linkage study to examine the utility of registers in Systemic Lupus Erythematosus (SLE) research and develop an extensive data repository for future epidemiologic investigations.
While maintaining a close collaboration with the Karolinska Institutet, she joined Stanford’s Epidemiology faculty in 2013. Dr. Simard studies outcomes such as malignancy, stroke, infection, and mortality, in patients with systemic autoimmune rheumatic diseases with a focus on systemic lupus erythematosus. Recently her primary research focus has shifted to the intersection between reproductive epidemiology and rheumatic disease fueled by a K01 career development award from the NIH (NIAMS) to study maternal and fetal outcomes in systemic lupus pregnancy. This led to collaborations with colleagues at Stanford, throughout the US, and abroad, and a series of projects focused on the diagnosis of preeclampsia and associated risks in pregnant women with systemic lupus. Dr. Simard was awarded a Peter Joseph Pappas Research Grant from the Preeclampsia Foundation for her lab's work examining preeclampsia risk in high-risk populations, and a McCormick Faculty Award from Stanford Medicine to take important steps towards disentangling preeclampsia from lupus nephritis. Dr. Simard is leading an international study of hydroxychloroquine in lupus pregnancy leveraging mixed methods in partnership with qualitative researchers, patients, clinicians, and epidemiologists in Sweden, Canada, and in the United States.
In addition to these issues of misclassification in reproductive rheumatology questions, Dr. Simard's lab is also interested in how misclassification, missed opportunities, and misdiagnosis contribute to disparities in complex conditions such as systemic lupus. In addition to methodologic issues around misclassification and bias and the largely clinical epidemiology focus of her work, Dr. Simard's work examines social determinants of health and health disparities. Dr. Simard was recently awarded an R01 from NIH (NIAID) to study the role of cognitive and unconscious bias in clinical decision making for female-predominant diseases including lupus.
